Industry News Helus Pharma Fierce Biotech
Helus Psychedelic Wins Phase 3 in Depression, but Serious Adverse Events Cloud It
- Phase 3 APPROACH tested HLP003, a deuterated psilocin, as add-on therapy for major depressive disorder in 222 adults.
- It showed a 7.6-point placebo-adjusted MADRS improvement at six weeks, meeting primary and key secondary endpoints.
- Three treatment-related serious adverse events occurred, all in the drug arm, one reportedly a suicide attempt; a second pivotal study reads out in Q4 2027.
A 7.6-point gap would be large for depression, but psychedelic trials struggle with unblinding, so functional unblinding and expectancy deserve scrutiny before the effect is believed. Safety is the bigger issue: three serious events versus none on placebo will draw FDA attention to monitoring and dosing-day supervision, whatever one case proves. Analysts split on that; EMBRACE is the real test.
Source: Fierce Biotech ↗ Helus' chemically modified psychedelic hits key goals in phase 3 depression trial